Release Notes:  Version 20210108


About this release 

This release (version 20210108) provides the latest updates to the Canadian Clinical Drug Data Set in English and French. This release also provides the addition of COVID-19 vaccine concepts within the existing CCDD files (TM, NTP, MP and relationship files), following the current Editorial Guidelines. Other vaccines are not being added at this time; however, work will continue on separate vaccine content.

A separate InfoScribe location for the French supporting documents, including the French Release Notes, can be found here

There is no change to the Technical Specification or the Editorial Guidelines.

The Canadian Clinical Drug Data Set is available for browsing and download via the Infoway Terminology Gateway.  

Supporting general information can be found on Infoway Canadian Clinical Drug Data Set InfoCentral page

General Notes

The following files are available as full release files within this version:

  • Manufactured Product,
  • Non-proprietary Therapeutic Product,
  • Therapeutic Moiety,
  • Manufactured Product-Non-proprietary Therapeutic Product-Therapeutic Product Relationship, in English (MP-NTP-TM Relationship),
  • Manufactured Product-Non-proprietary Therapeutic Product-Therapeutic Product Relationship, in French (Relation PM-PTC-FT), 
  • Special Groupings, 
  • Coded Attribute, and
  • Device Non-proprietary Therapeutic Product.

The "Full" release contains one entry for every concept that has ever been released and new content added for that release. New content added for a specific release may at times include “Inactive” content.

NOTE:  The “Delta" release which is intended to contain only those concepts that have been added or changed since the previous release will be considered for a future enhancement at a later date.  

This release reflects additions and changes that have occurred in DPD since the last CCDD release.  



Questions, Concerns, Changes

Questions and concerns and suggestions for future consideration are welcomed and should be sent by e-mail at [email protected]

  • No labels